Bio-Techne stock kpis
Want to see TECH full AI Analyst Report?
Revenue by Segment
Bio-Techne reported revenue by segment of $299.71M in Q1 FY2027, down 6.7% from Q4 FY2026 and up 4.6% year over year. The highest value was $321.19M in Q4 FY2026.
Breaks total sales into the company’s product or business-line categories so you can see which areas drive growth and which lag. Useful for assessing diversification, dependence on key products, and where management is allocating resources to expand or defend market share.
Protein Sciences is the clear revenue anchor—steady, resilient and recovering after cyclical dips—while Diagnostics & Spatial Biology is the fastest-growing diversifier, delivering consistent quarter-to-quarter expansion that should underpin long-term margin improvement. Small 'Other' contributions and large swings in intersegment eliminations look like accounting/reclassification noise (and one apparent 2026‑Q1 Protein Sciences data anomaly); don’t mistake those blips for underlying operating momentum—watch core segment trends and underlying bookings for true signal.
TECH Revenue by Segment
| Period | Other | Intersegment | Protein Sciences | Diagnostics and Spatial Biology | Total |
|---|---|---|---|---|---|
| Q1 FY2027Sep 30, 2026 | $0.00 | -$143.00K | $219.69M | $80.16M | $299.71M |
| Q4 FY2026Jun 30, 2026 | $0.00 | -$144.00K | $231.19M | $90.14M | $321.19M |
| Q3 FY2026Mar 31, 2026 | $0.00 | -$325.00K | $221.54M | $85.59M | $306.80M |
| Q2 FY2026Dec 31, 2025 | $0.00 | -$387.00K | $215.08M | $81.18M | $295.88M |
| Q1 FY2026Sep 30, 2025 | $5.44M | -$530.00K | $202.19M | $79.46M | $286.56M |
| Q4 FY2025Jun 30, 2025 | $0.00 | $787.00K | $226.47M | $89.70M | $316.96M |
| Q3 FY2025Mar 31, 2025 | $0.00 | -$737.00K | $227.69M | $89.23M | $316.18M |
| Q2 FY2025Dec 31, 2024 | $1.85M | -$504.00K | $211.55M | $84.14M | $297.03M |
| Q1 FY2025Sep 30, 2024 | $2.30M | -$572.00K | $204.53M | $83.19M | $289.46M |
| Q4 FY2024Jun 30, 2024 | $2.06M | -$628.00K | $213.99M | $90.68M | $306.10M |
| Q3 FY2024Mar 31, 2024 | $2.09M | -$765.00K | $214.59M | $87.51M | $303.43M |
| Q2 FY2024Dec 31, 2023 | $0.00 | -$480.00K | $197.67M | $75.41M | $272.60M |
| Q1 FY2024Sep 30, 2023 | $0.00 | -$517.00K | $204.66M | $72.80M | $276.94M |
| Q4 FY2023Jun 30, 2023 | $0.00 | -$713.00K | $223.01M | $79.03M | $301.32M |
| Q3 FY2023Mar 31, 2023 | $0.00 | -$426.00K | $218.90M | $75.67M | $294.15M |
| Q2 FY2023Dec 31, 2022 | $0.00 | -$309.00K | $203.89M | $68.00M | $271.58M |
| Q1 FY2023Sep 30, 2022 | $0.00 | -$198.00K | $199.95M | $69.90M | $269.65M |
| Q4 FY2022Jun 30, 2022 | $0.00 | -$402.00K | $216.98M | $71.65M | $288.23M |
| Q3 FY2022Mar 31, 2022 | $0.00 | -$479.00K | $213.18M | $77.68M | $290.38M |
| Q2 FY2022Dec 31, 2021 | $0.00 | -$222.00K | $204.97M | $64.53M | $269.28M |
| Q1 FY2022Sep 30, 2021 | $0.00 | -$452.00K | $197.19M | $60.98M | $257.72M |
| Q4 FY2021Jun 30, 2021 | $0.00 | -$345.00K | $192.32M | $67.06M | $259.03M |
| Q3 FY2021Mar 31, 2021 | $0.00 | -$164.00K | $185.62M | $58.09M | $243.55M |
| Q2 FY2021Dec 31, 2020 | $0.00 | -$395.00K | $172.18M | $52.47M | $224.25M |
| Q1 FY2021Sep 30, 2020 | $0.00 | -$372.00K | $154.45M | $50.13M | $204.20M |

